Moreno F, Iranzo V, Álvarez I, Antón A, Chacón J I, Gavilá J, Martín M, Sánchez Rovira P, Gratal P, Fernández González M J, López R
Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
Medical Oncology Department, Consorcio Hospital General Universitario, Valencia, Spain.
Clin Transl Oncol. 2025 Mar 27. doi: 10.1007/s12094-025-03896-z.
To assess the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in routine clinical practice in Spain, as well as the perceptions from oncologists.
A survey was developed by nine oncologists, experts in breast cancer, practising in Spain. Survey responses were collected between July 2022 and April 2023.
Fifty-one survey responses were obtained. Most oncologists used CDK4/6 inhibitors in the first line. The first-line endocrine therapy most frequently used was an aromatase inhibitor (endocrine-sensitive disease) and fulvestrant (endocrine-resistant disease). CDK4/6 inhibitors were used for primary or secondary resistance, or visceral disease without visceral crisis. A lower-than-standard starting dose was considered (57% of respondents) for specific profiles. Strategies to manage toxicity included switching to another CDK4/6 inhibitor or delaying the next dose. CDK4/6 inhibitors were mostly considered to improve quality of life.
Use of CDK4/6 inhibitors in Spain follows current recommendations and aligns with the evidence.
评估细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂在西班牙常规临床实践中的使用情况以及肿瘤学家的看法。
由九位在西班牙执业的乳腺癌专家肿瘤学家开展了一项调查。在2022年7月至2023年4月期间收集了调查回复。
获得了51份调查回复。大多数肿瘤学家在一线治疗中使用CDK4/6抑制剂。最常用的一线内分泌治疗是芳香化酶抑制剂（内分泌敏感型疾病）和氟维司群（内分泌抵抗型疾病）。CDK4/6抑制剂用于原发性或继发性耐药，或无内脏危象的内脏疾病。对于特定情况，有57%的受访者考虑采用低于标准的起始剂量。管理毒性的策略包括换用另一种CDK4/6抑制剂或推迟下一次给药。CDK4/6抑制剂大多被认为可改善生活质量。
西班牙对CDK4/6抑制剂的使用遵循当前建议并与证据相符。
